Biodesix to Present at Canaccord Genuity’s 44th Annual Growth Conference
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The event is scheduled for August 13-14, 2024, at the InterContinental Boston, MA.
CEO Scott Hutton will represent Biodesix in a fireside chat on Wednesday, August 14, 2024, at 1:00 PM ET. Additionally, the company will host in-person 1x1 investor meetings during the conference. Investors and interested parties can access a live webcast of the presentation through the 'News & Events' section of Biodesix's website, with a replay option available afterwards.
This participation underscores Biodesix's commitment to engaging with the investment community and showcasing its advancements in lung disease diagnostics.
Biodesix (Nasdaq: BDSX), un'azienda leader nelle soluzioni diagnostiche focalizzata sulle malattie polmonari, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. L'evento si terrà il 13 e 14 agosto 2024, presso l'InterContinental di Boston, MA.
Il CEO Scott Hutton rappresenterà Biodesix in un'intervista informale mercoledì 14 agosto 2024, alle 13:00 ET. Inoltre, l'azienda ospiterà incontri individuali di persona con gli investitori durante la conferenza. Gli investitori e i soggetti interessati possono accedere a una trasmissione in diretta della presentazione attraverso la sezione 'News & Events' del sito web di Biodesix, con opzione di replay disponibile in seguito.
Questa partecipazione sottolinea l'impegno di Biodesix nel coinvolgere la comunità degli investitori e nel mostrare i suoi progressi nelle diagnosi delle malattie polmonari.
Biodesix (Nasdaq: BDSX), una empresa líder en soluciones diagnósticas centradas en enfermedades pulmonares, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El evento está programado para los 13 y 14 de agosto de 2024, en el InterContinental de Boston, MA.
El CEO Scott Hutton representará a Biodesix en un chat informal el miércoles 14 de agosto de 2024, a la 1:00 PM ET. Además, la empresa llevará a cabo reuniones individuales presenciales con inversores durante la conferencia. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección 'News & Events' del sitio web de Biodesix, con una opción de repeticiones disponible posteriormente.
Esta participación subraya el compromiso de Biodesix de involucrarse con la comunidad inversora y mostrar sus avances en la diagnóstico de enfermedades pulmonares.
Biodesix (Nasdaq: BDSX), 폐 질환에 중점을 둔 선도적인 진단 솔루션 회사가 Canaccord Genuity의 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 8월 13일부터 14일까지 보스턴 MA의 인터컨티넨탈 호텔에서 열릴 예정입니다.
CEO Scott Hutton은 2024년 8월 14일 수요일 오후 1:00 ET에 진행되는 파이어사이드 차트에서 Biodesix를 대표합니다. 또한, 회사는 컨퍼런스 동안 투자자와의 인-person 1:1 미팅을 주최합니다. 투자자와 관심 있는 사람들은 Biodesix 웹사이트의 'News & Events' 섹션에서 발표의 실시간 웹캐스트에 접근할 수 있으며, 이후 리플레이 옵션도 제공됩니다.
이번 참여는 Biodesix가 투자 커뮤니티와의 소통을 강화하고 폐 질환 진단의 발전을 선보이겠다는 의지를 강조합니다.
Biodesix (Nasdaq: BDSX), une entreprise leader dans les solutions de diagnostic axées sur les maladies pulmonaires, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. L'événement est prévu pour le 13 et 14 août 2024, à l'InterContinental de Boston, MA.
Le PDG Scott Hutton représentera Biodesix lors d'une discussion informelle le mercredi 14 août 2024 à 13h00 ET. De plus, l'entreprise organisera des réunions individuelles en personne avec des investisseurs pendant la conférence. Les investisseurs et les parties intéressées peuvent accéder à une diffusion en direct de la présentation par le biais de la section 'News & Events' du site web de Biodesix, avec une option de rediffusion disponible par la suite.
Cette participation souligne l'engagement de Biodesix à dialoguer avec la communauté des investisseurs et à mettre en avant ses avancées dans le domaine du diagnostic des maladies pulmonaires.
Biodesix (Nasdaq: BDSX), ein führendes Unternehmen für Diagnoselösungen mit Fokus auf Lungenerkrankungen, hat seine Teilnahme an der 44. Jahreskonferenz für Wachstum von Canaccord Genuity bekannt gegeben. Die Veranstaltung ist für den 13. und 14. August 2024 im InterContinental in Boston, MA, geplant.
CEO Scott Hutton wird Biodesix in einem Gespräch am Kamin am Mittwoch, den 14. August 2024, um 13:00 Uhr ET vertreten. Darüber hinaus wird das Unternehmen persönliche 1x1-Investorenmeetings während der Konferenz veranstalten. Investoren und Interessierte können über den Bereich 'News & Events' auf der Website von Biodesix auf einen Live-Webcast der Präsentation zugreifen, der danach auch als Wiederholung verfügbar ist.
Diese Teilnahme unterstreicht Biodesix' Engagement, mit der Investoren-Community in Kontakt zu treten und seine Fortschritte in der Diagnostik von Lungenerkrankungen zu präsentieren.
- None.
- None.
Canaccord Genuity’s 44th Annual Growth Conference
Fireside Chat Date: Wednesday, August 14, 2024
Fireside Chat Time: 1:00 PM ET
Location: InterContinental Boston,
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix's website at Biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
The Biodesix logo, Biodesix, Nodify Lung, Nodify XL2, Nodify CDT, IQLung, GeneStrat, GeneStrat NGS, and VeriStrat are trademarks or registered trademarks of Biodesix, Inc. The ddPCR technology is a trademark of Bio-Rad Laboratories.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, expectations regarding revenue and margin growth and its impact on profitability, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806872538/en/
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
1-339-970-2843
Source: Biodesix, Inc.
FAQ
When and where is Biodesix (BDSX) presenting at Canaccord Genuity's 44th Annual Growth Conference?
Who will be representing Biodesix (BDSX) at the Canaccord Genuity conference?
How can investors access Biodesix's (BDSX) presentation at the Canaccord Genuity conference?
What is the focus of Biodesix (BDSX) as a diagnostic solutions company?
